TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11259736

Group type: EXPERIMENTAL
Intervention: Oral glucose loading (75 g) in pregnant women
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral glucose loading (75 g) in non-pregnant women
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral glucose loading (75 g)
Number of subjects: 30
Study: 9676408

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (TURP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (TUVP)
Number of subjects: 60
Study: 7991315

Group type: EXPERIMENTAL
Intervention: Abstract paintings
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Realistic paintings
Number of subjects: 51
Study: 3059399

Group type: EXPERIMENTAL
Intervention: iopamidol (IOP, 20 cases)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 76% Na‐meglumine diatrizoate (76% UG, 20 cases)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 38% Na‐meglumine diatrizoate (38% UG, 10 cases)
Number of subjects: 50
Study: 31762210

Group type: EXPERIMENTAL
Intervention: Neuropathy questionnaires (NQ) and nerve conduction studies (NCS) in patients with RD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neuropathy questionnaires (NQ)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 100
Study: 30061289

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir for 8, 12, or 16 weeks
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir for 12 weeks
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir regimen
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Number of subjects: 2200
Study: 28751099

Group type: EXPERIMENTAL
Intervention: DMF 240 mg BID
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study: 26632295

Group type: EXPERIMENTAL
Intervention: Local anesthesia simulation model (experimental group, N=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Local anesthesia administered by students who practiced on the simulation model (experimental group, N=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (N=30)
Number of subjects: 60
Study: 23945891

Group type: EXPERIMENTAL
Intervention: Acetazolamide (25 mg/kg/day) started in the first 48 hours after admission
Number of subjects: 57

Group type: COMPARATOR
Intervention: Acetazolamide (25 mg/kg/day) administered after the first 48 hours
Number of subjects: 57
Study: 20864468

Group type: EXPERIMENTAL
Intervention: Work Style (WS) intervention
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Work Style plus Physical Activity (WSPA) intervention
Number of subjects: 466

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 466
Study: 19084098

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 162
Study: 16781228

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive contemporary management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibition started early post-coronary artery bypass graft
Number of subjects: 0
Study: 11773209

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (EX)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nutrition education program (NU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (EX and NU)
Number of subjects: 100
Study: 10359339

Group type: EXPERIMENTAL
Intervention: Grating acuity assessment
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: HOTV letter acuity assessment
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: ETDRS letter acuity assessment
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Overall interobserver agreement
Number of subjects: 73
Study: 7491394

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Live ratings
Number of subjects: 8

Group type: COMPARATOR
Intervention: Videotape ratings
Number of subjects: 8
Study: 2387675

Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Pyridoxine and Riboflavin supplementation in subjects with initially deficient biochemical vitamin status
Number of subjects: 113
Study: 7264274

Group type: EXPERIMENTAL
Intervention: Oral diethylcarbamazine (DEC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical diethylcarbamazine (DEC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levamisole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yeast tablets
Number of subjects: 0
Study: 29536140

Group type: EXPERIMENTAL
Intervention: PFMT and VTT
Number of subjects: 48

Group type: COMPARATOR
Intervention: PFMT
Number of subjects: 48
Study: 28685204

Group type: EXPERIMENTAL
Intervention: Prasugrel (loading dose 20 mg, maintenance dose 3.75 mg/day for 7 days)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prasugrel (maintenance dose 3.75 mg/day for 7 days)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day after switching from prasugrel)
Number of subjects: 45
Study: 25537736

Group type: EXPERIMENTAL
Intervention: air-Q
Number of subjects: 96

Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 96
Study: 25455003

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg bid
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo bid
Number of subjects: 135
Study: 22520621

Group type: EXPERIMENTAL
Intervention: Resveratrol-rich grape supplement (resveratrol 8 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional grape supplement lacking resveratrol
Number of subjects: 75
Study: 19525871

Group type: EXPERIMENTAL
Intervention: L reuteri (1 x 10 CFU)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 17544870

Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg/day for 12 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 48
Study: 15338850

Group type: EXPERIMENTAL
Intervention: Amiodarone plus pacing
Number of subjects: 160

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pacing
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 11438377

Group type: EXPERIMENTAL
Intervention: Danazol (600 mg daily for 6 months)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate depot (3.75 mg every 28 days for 6 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Post-treatment (3 months after termination of both treatments)
Number of subjects: 38
Study: 9053474

Group type: EXPERIMENTAL
Intervention: Salvage treatments after MOPP-ABVD
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Initial chemotherapy re-treatment
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy or new regimens
Number of subjects: 115
Study: 8429117

Group type: COMPARATOR
Intervention: Placebo twice daily (bid)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg bid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg bid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid
Number of subjects: 12
Study: 3619738

Group type: EXPERIMENTAL
Intervention: 1% forskolin (colforsin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (untreated eye)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Forskolin (treated eye)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Timolol pretreatment (placebo-treated eye)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Timolol pretreatment (forskolin-treated eye)
Number of subjects: 15
Study: 30783676

Group type: EXPERIMENTAL
Intervention: TAK-003 (live-attenuated tetravalent dengue vaccine candidate)
Number of subjects: 0
Study: 30807638

Group type: EXPERIMENTAL
Intervention: Fellow eyes of patients with unilateral RVO
Number of subjects: 83
Study: 27649463

Group type: EXPERIMENTAL
Intervention: Virtual surgical planning (VSP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional planning
Number of subjects: 16
Study: 25765588

Group type: EXPERIMENTAL
Intervention: High-zone programming group (VT1: 171-200 bpm, VT2: 200-230 bpm, VF: >230 bpm)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: High-zone programming group
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional programming group (VT1: 167-182 bpm, VT2: 182-200 bpm, VF: >200 bpm)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional programming group
Number of subjects: 223
Study: 23819241

Group type: EXPERIMENTAL
Intervention: Auricular point sticking with vaccaria seeds applied at Shenmen (TF 4), Wei (CO 4), and Jiaogan (AH 6a) before the operation and at 1, 5, 9, 23 hours after the operation, pressed for 5 minutes each point each time.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo group with the same point selection and sticking paste but no sticking or pressing with vaccaria seeds.
Number of subjects: 120
Study: 21289258

Group type: EXPERIMENTAL
Intervention: 60 mg denosumab every 6 months for 24 months
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Denosumab (after discontinuation)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Denosumab and Placebo (off-treatment phase)
Number of subjects: 256
Study: 19814758

Group type: EXPERIMENTAL
Intervention: Brief motivation interview by a trained interventionist and an injury prevention brochure (Intervention Group - IG)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Injury prevention brochure only (Control Group - CG)
Number of subjects: 292
Study: 16632297

Group type: EXPERIMENTAL
Intervention: 100 mg zinc sulfate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Starch as placebo
Number of subjects: 0
Study: 14754691

Group type: EXPERIMENTAL
Intervention: 0.3 mg synthetic conjugated estrogens
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 0.625 mg synthetic conjugated estrogens
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 1.25 mg synthetic conjugated estrogens
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 10910019

Group type: EXPERIMENTAL
Intervention: Selective adsorption (SA) followed by intravenous immunoglobulin (i.v. IgG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Selective adsorption (SA) using a tryptophan-linked polyvinyl alcohol gel adsorbent
Number of subjects: 45
Study: 9062837

Group type: EXPERIMENTAL
Intervention: Normal three meals per day containing usual energy intake
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: One meal per day (dinner time) containing 50% of usual energy intake
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Three meals per day containing 50% of usual energy intake
Number of subjects: 4
Study: 8112969

Group type: EXPERIMENTAL
Intervention: Oral pefloxacin 400 mg
Number of subjects: 20
Study: 3511312

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2456122

Group type: EXPERIMENTAL
Intervention: Transurethral prostatotomy (TUT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Transurethral prostatectomy (TUR)
Number of subjects: 49
Study: 30928413

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CAF [cyclophosphamide, doxorubicin, 5‐fluorouracil] vs. CMF [cyclophosphamide, methotrexate, 5‐fluorouracil])
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment (subgroup analysis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study: 28428093

Group type: EXPERIMENTAL
Intervention: tONS at 2 Hz
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: tONS at 100 Hz
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: tONS at 2/100 Hz
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Topiramate orally
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham tONS
Number of subjects: 110
Study: 25776729

Group type: EXPERIMENTAL
Intervention: Clonidine transdermal patch (test formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonidine transdermal patch (reference formulation)
Number of subjects: 0
Study: 23195993

Group type: EXPERIMENTAL
Intervention: Nickel refinery workers
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 18
Study: 21646329

Group type: EXPERIMENTAL
Intervention: Unilateral subdural motor cortex stimulation
Number of subjects: 11
Study: 19114687

Group type: EXPERIMENTAL
Intervention: Radiotherapy (cumulative dose, 50 Gy)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control (no radiotherapy)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control
Number of subjects: 264
Study: 16988209

Group type: COMPARATOR
Intervention: Omeprazole (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lansoprazole (60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: S18982 (active metabolite)
Number of subjects: 0
Study: 15080820

Group type: EXPERIMENTAL
Intervention: Butterbur (BB) 50 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fexofenadine (FEX) 180 mg once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study: 10835090

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (betamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 9258847

Group type: EXPERIMENTAL
Intervention: Concentric training (C‐E/C, n = 13)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Eccentric training (C‐E/E, n = 13)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of concentric and eccentric training (C‐E/‐E, n = 11)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 37
Study: 8336751

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg per day)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 3522723

Group type: EXPERIMENTAL
Intervention: Single vaginal application of a suppository containing 10 mg of 9‐deoxo‐16‐PGE2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate side effects occurred in the majority of treated patients
Number of subjects: 0
Study: 30115670

Group type: EXPERIMENTAL
Intervention: Multibite (MB) forceps
Number of subjects: 21

Group type: COMPARATOR
Intervention: Single-bite (SB) forceps
Number of subjects: 21
Study: 27474961

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 20-70mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 25103303

Group type: EXPERIMENTAL
Intervention: RDTs with basic clinician training (1 day)
Number of subjects: 3982

Group type: EXPERIMENTAL
Intervention: RDTs with enhanced clinician training (3 days)
Number of subjects: 3982

Group type: COMPARATOR
Intervention: Control group (current practice with microscopy)
Number of subjects: 3982
Study: 22376226

Group type: EXPERIMENTAL
Intervention: Vision restoration therapy (VRT) combined with active tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vision restoration therapy (VRT) paired with sham tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active tDCS combined with VRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS paired with VRT
Number of subjects: 0
Study: 19581542

Group type: EXPERIMENTAL
Intervention: Xylitol topical oral syrup (2 xylitol [4.00-g] doses and 1 sorbitol dose) administered twice a day (Xyl-2x group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Xylitol topical oral syrup (3 xylitol [2.67-g] doses) administered thrice a day (Xyl-3x group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control syrup (1 xylitol [2.67-g] dose and 2 sorbitol doses)
Number of subjects: 100
Study: 17456686

Group type: EXPERIMENTAL
Intervention: USG alone (Group U)
Number of subjects: 72

Group type: COMPARATOR
Intervention: USG combined with neurostimulation (Group S)
Number of subjects: 72
Study: 15006037

Group type: EXPERIMENTAL
Intervention: Experimental subjects (multiple motor learning experiences)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (limited motor learning experiences)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental subjects
Number of subjects: 0
Study: 11815975

Group type: EXPERIMENTAL
Intervention: Treatment in older cohorts (age > 70 years)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Older cohorts (age > 70 years)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Patients in the oldest cohort (age > 70 years)
Number of subjects: 515
Study: 10847988

Group type: EXPERIMENTAL
Intervention: Experimental group (program promoting social competence)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study: 7752587

Group type: EXPERIMENTAL
Intervention: rhIGF-1, 50 micrograms/kg body weight
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhIGF-1, 100 micrograms/kg body weight
Number of subjects: 18
Study: 2271202

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.1 MAC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Halothane (0.85%)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Enflurane (1.85%)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isoflurane (1.27%)
Number of subjects: 32
Study: 6446314

Group type: EXPERIMENTAL
Intervention: Metronidazole 200 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oxytetracycline 250 mg twice daily
Number of subjects: 40
Study: 30882339

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise program (30 minutes, 5 days per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Exercise program (60 minutes, at least 3 days a week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27777183

Group type: EXPERIMENTAL
Intervention: Higher intake of butter and margarine
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Total vitamin D intake
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Fish and shellfish intake
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Overall vitamin D intake from foods
Number of subjects: 595
Study: 26863502

Group type: EXPERIMENTAL
Intervention: Continuous infusion (8 mL/h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Automated hourly boluses (8 mL/bolus)
Number of subjects: 24
Study: 23975091

Group type: EXPERIMENTAL
Intervention: Ultrasonography analysis of fascial thickness
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ultrasonography analysis of sub-layers of fascia
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ultrasonography analysis of SCM fascia
Number of subjects: 53
Study: 22407438

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adolescent-focused therapy (AFT)
Number of subjects: 0
Study: 19240517

Group type: EXPERIMENTAL
Intervention: Quilting suture (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No quilting suture (Group B)
Number of subjects: 30
Study: 17513814

Group type: EXPERIMENTAL
Intervention: Oral topotecan 2.3 mg/m2/d on days 1 through 5 every 21 days
Number of subjects: 309

Group type: COMPARATOR
Intervention: IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days
Number of subjects: 309
Study: 15175536

Group type: EXPERIMENTAL
Intervention: Omni cigarette
Number of subjects: 34

Group type: COMPARATOR
Intervention: Own cigarettes
Number of subjects: 34
Study: 11445471

Group type: EXPERIMENTAL
Intervention: Durasphere
Number of subjects: 355

Group type: COMPARATOR
Intervention: Bovine collagen
Number of subjects: 355
Study: 9520191

Group type: EXPERIMENTAL
Intervention: Topical 0.1% dexamethasone, polymyxin B (6,000 U/ml), and 0.5% neomycin 4 times a day for 1 week after RK or PRK
Number of subjects: 82

Group type: COMPARATOR
Intervention: Polymyxin B (6,000 U/ml) and 0.5% neomycin for 1 week after RK or PRK
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Topical 0.1% dexamethasone, polymyxin B (6,000 U/ml), and 0.5% neomycin 4 times a day for 15 days after LASIK
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Phototherapeutic keratectomy (PTK)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Microperforations during RK
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Limbal bleeding during RK
Number of subjects: 82
Study: 8206767

Group type: EXPERIMENTAL
Intervention: Ambulation at 3 hours after cardiac angiogram
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ambulation at 6 hours after cardiac angiogram
Number of subjects: 39
Study: 2914543

Group type: EXPERIMENTAL
Intervention: Salsalate (1.5 g twice a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Enteric-coated aspirin (650 mg four times a day)
Number of subjects: 10
Study: 31423722

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 0
Study: 29058298

Group type: EXPERIMENTAL
Intervention: Test formulation A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test formulation B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 0
Study: 25886590

Group type: EXPERIMENTAL
Intervention: Combined diet and PA intervention
Number of subjects: 183